- Home
- Supplements
- Bitter Melon
- Type 2 Diabetes
Bitter Melon for Type 2 Diabetes
Bitter melon lowers glucose convincingly in laboratory models and unconvincingly in people. The most informative trial found it significantly less effective than metformin, and systematic review concluded the evidence base cannot support a recommendation.
Overview
Verdict
Not recommended as a glucose-lowering therapy. Cochrane found evidence insufficient and it underperformed metformin head to head.
How It Works
Dosing & Protocol
Typical dose
- Recommended dose
- 1,000-2,000 mg/day standardised extract before meals
- Expected timeframe
- 12 weeks; if HbA1c is unchanged, stop
Protocol
- timing
- Before meals
- starting dose
- 500 mg twice daily before meals
- typical range
- 1,000-2,000 mg/day
- assessment point
- HbA1c at 12 weeks; discontinue if unchanged
Evidence
What the studies say
Momordica charantia for type 2 diabetes mellitus: hypoglycemic efficacy and safety in patients with type 2 diabetes mellitus
Kim SK, Jung J, Jung JH +2 more
After treatment with bitter melon extract for 12 weeks, the HbA1c levels of the bitter melon and placebo groups remained unchanged; however, the average fasting glucose level of the bitter melon group decreased (p = 0.014).
Momordica charantia Administration Improves Insulin Secretion in Type 2 Diabetes Mellitus
Cortez-Navarrete M, Martínez-Abundis E, Pérez-Rubio KG +2 more
A significant increase in insulin AUC (56,562 ± 36,078 vs. 65,256 ± 42,720 pmol/L/min, P = .043)
Momordica charantia for type 2 diabetes mellitus
Ooi CP, Yassin Z, Hamid TA
There is insufficient evidence to recommend Momordica charantia for type 2 diabetes; trials showed no statistically significant difference in glycaemic control versus placebo or metformin.
Effects of Momordica charantia L. supplementation on glycemic control and lipid profile in type 2 diabetes mellitus patients: A systematic review and meta-analysis of randomized controlled trials
Nagarani G, et al.
Pooled results suggested a small reduction in fasting blood glucose with M. charantia but no significant change in HbA1c or lipid profile, with GRADE certainty rated low.
Safety
Caveats
The main risk here is substitution — delaying or displacing effective therapy in favour of a marginal one. Seeds contain vicine, a haemolysis risk in G6PD deficiency.
Less likely to help if
Medical Disclaimer
The information provided on this website is for educational and informational purposes only and is not intended as a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition or before starting any supplement regimen.
Individual results may vary. The statements on this website have not been evaluated by the Food and Drug Administration. Products and information are not intended to diagnose, treat, cure, or prevent any disease.